Francesca Maria Orlandella
Overview
Explore the profile of Francesca Maria Orlandella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gallo E, Smaldone G, Cimmino L, Braile M, Orlandella F, Luciano N, et al.
Pharmaceutics
. 2025 Feb;
17(2).
PMID: 40006633
Thyroid cancer (TC) is the most prevalent endocrine malignancy, and is categorized into well-differentiated and aggressive anaplastic types. Novel therapeutic modalities are needed for TC. Nanomedicine is a promising strategy...
2.
Su Q, Orlandella F, Smaldone G, Qi Y
Front Mol Biosci
. 2024 Dec;
11:1533057.
PMID: 39698110
No abstract available.
3.
Luciano N, Orlandella F, Braile M, Cavaliere C, Aiello M, Franzese M, et al.
J Transl Med
. 2024 Nov;
22(1):1088.
PMID: 39616372
Background: There is a growing interest on the association of radiomic features with genomic signatures in oncology. Using computational methods, quantitative radiomic data are extracted from various imaging techniques and...
4.
Mancini A, Orlandella F, Vitucci D, Luciano N, Alfieri A, Orru S, et al.
Front Oncol
. 2024 Nov;
14:1479454.
PMID: 39555455
Lung cancer is the major cause of cancer-related deaths worldwide with an estimated 1.8 million deaths and 2.4 million new cases in 2022. Poor cardiorespiratory fitness, dyspnea and fatigue are...
5.
Braile M, Luciano N, Carlomagno D, Salvatore G, Orlandella F
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000555
Among the non-coding RNAs, the aberrant expression of microRNAs (miRNAs) is well described in the oncology field. It is clear that the altered expression of miRNAs is crucial for a...
6.
Orlandella F, Imperlini E, Pane K, Luciano N, Braile M, De Stefano A, et al.
Biomedicines
. 2024 Mar;
12(3).
PMID: 38540271
During tumorigenesis, miRNAs with unbalanced expression profiles can increase the threat of disease progression. Here, we focus on the role of miR-331-5p in the pathogenesis of thyroid cancer (TC). In...
7.
Orlandella F, De Stefano A, Braile M, Luciano N, Mancini A, Franzese M, et al.
Crit Rev Oncol Hematol
. 2022 Oct;
180:103844.
PMID: 36244643
Purpose: Since cancer-related miRNAs expression are affected by physical activity/exercise, they represent an attractive tool to monitor this response in healthy and in cancer subjects. Here, we aim to update...
8.
Affinito O, Orlandella F, Luciano N, Salvatore M, Salvatore G, Franzese M
Cancer Cell Int
. 2022 Aug;
22(1):263.
PMID: 35996174
Background: Intra-tumor heterogeneity (ITH) results from the continuous accumulation of mutations during disease progression, thus impacting patients' clinical outcome. How the ITH evolves across papillary thyroid carcinoma (PTC) different tumor...
9.
Orlandella F, Mirabelli P, De Stefano A, Iervolino P, Luciano N, DAngelo S, et al.
Oxid Med Cell Longev
. 2022 Feb;
2022:6268755.
PMID: 35222800
Among natural macromolecules, the polyphenol extract from flesh (FPE) apple could play a potential therapeutic role for a large spectrum of human cancer also by exerting antioxidant properties. Thyroid cancer...
10.
Orlandella F, Auletta L, Greco A, Zannetti A, Salvatore G
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885130
Background: We have conducted a systematic review focusing on the advancements in preclinical molecular imaging to study the delivery and therapeutic efficacy of miRNAs in mouse models of breast cancer....